Nova matches university research with global commercialization opportunities.
An AI platform for research commercialization, developed with Zima Labs. Nova assesses a patent's licensing potential against market evidence and finds the licensees that fit, in minutes, not weeks.
What Nova does
Qualified leads and personalized pitch decks, from one question.
Nova runs patent analysis and IP evaluation across a university's entire portfolio, scores each asset for commercialization readiness against the competition, shortlists licensees and investors, and puts together marketing materials tailored to each prospect.
-
Ask
Ask in plain language, from a field or a single invention.
Which inventions help CAR-T cells survive longer in patients, and who would license them?
Invention Immuno-oncology · CAR-T -
Evaluate
Licensable or not, on what evidence, against whom.
Licensing · Evaluate
Selective expansion switch for engineered immune cells
Licensee interest 88/100 · HighCompetitive intensity High5 franchises4 trials3 public statements -
Match
To whom, ranked with reasons, from deals and pipelines on the record.
Licensing · Lead gen
Candidate licensees
StrongComplementary fit3
- 1Global pharma, CAR-T franchise91/100 fitOwns two approved CAR-T products. Actively scouting persistence enhancers.
- 2Biotech, cell-therapy platform85/100 fitPrioritizing durability for its CAR-T portfolio. Complementary, not competing.
- 3Large pharma, next-gen cell therapy72/100 fit
-
Outreach
An email and a deck, drafted per licensee, ready to send.
Cover email
Helping CAR-T cells survive longer in patients
Draft in GmailProposal deck
A built-in switch that makes CAR-T cells multiply and persist.
Developed with Zima Labs
Nova is powered by Zima Labs, the unified intelligence above an organization's data.
Ready to transform your legacy data into insight that acts and edge that compounds?